Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC

NCT04997382 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

112

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
DRUG: Chemotherapy alone or Chemotherapy with or without Bevacizumab

Sponsor

Hunan Province Tumor Hospital